Marinus Pharmaceuticals — Corporate Update (September 2017)
15 slides from Marinus Pharmaceuticals's corporate update, Sep 11, 2017
Slide 1: Safe Harbor Statement
Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private
Slide 2: Agenda
Agenda Introduction Christopher M. Cashman, CEO Phase 2 clinical trial design & data Dr. Lorianne Masuoka, CMO Case summaries of patients w/ CDKL5 disorder Dr. Nicola Specchio, Principal Investigator, Ospedale Pediatrico Bambino Gesù, Rome Closing Remarks Christopher M. Cashman, CEO 2
Slide 3: Marinus's Development of Ganaxolone
Marinus’s Development of Ganaxolone 3 Clear efficacy signal in refractory, CDKL5 disorder Need for mechanistically novel, efficacious & safe treatment options Committed to improving lives of patients with refractory epilepsies and psychiatric disorders
Slide 4: Ganaxolone in children with CDKL5 Disorder
Ganaxolone in children with CDKL5 Disorder Dr. Lorianne Masuoka, CMO
Slide 5: Ganaxolone Targets Synaptic and Extrasynaptic GABAA Receptors
5 Ganaxolone (GNX) Targets Synaptic and Extrasynaptic GABAA Receptors GNX is a synthetic analog of allopregnanolone GNX is designed to modulate both synaptic and extrasynaptic GABAA receptors to calm over-excited neurons
Slide 6: CDKL5 Disorder – Rare, serious epileptic condition
CDKL5 Disorder – Rare, serious epileptic condition 6 Cause Mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome Symptoms Early-onset, difficult-to-control seizures, & severe neuro-developmental impairment Most can’t walk, talk or care for themselves Suffer from sc
Slide 7: Phase 2 Study in CDKL5 Disorder
Phase 2 Study in CDKL5 Disorder Trial Design: 2 sites in US; 1 site in Italy Oral ganaxolone - up to 1,800 mg/day + existing treatment regimen 6 females, 1 male; ages 2-16 Enrollment criteria: Confirmed CDKL5 mutation, stable background treatment, >4 seizures per 28-day period in baseline Endpoints:
Slide 8: CDKL5 Disorder - Phase 2 Efficacy Data
CDKL5 Disorder - Phase 2 Efficacy Data (as of Sept 11, 2017) 8 One-Year Extension Enrollees N=3* Median Seizure reduction 70% Median increase in seizure-free days 75% ITT Analysis N=7 Median seizure reduction from baseline 43% Median increase in seizure-free days 78% *One high responder is still und
Slide 9: CDKL5 Disorder - Phase 2 Safety Profile
CDKL5 Disorder - Phase 2 Safety Profile (as of Sept 11, 2017) Generally safe and well-tolerated No serious adverse events No reports of somnolence or dizziness (the most frequently reported AE in prior studies) Two patients discontinued prior to completing the 26-week treatment due to lack of effica
Slide 10: Case summaries
Case summaries Dr. Nicola Specchio Principal Investigator, Ospedale Pediatrico Bambino Gesù in Rome
Slide 11: 8-Year Old Female
8-Year Old Female Pre-ganaxolone treatment Post-ganaxolone treatment % Change Seizures daily spasms and tonic spasms spasms almost disappeared; improvement in attention and interaction; child shows affection Seizure frequency (per 28 days) 155 23 85% decrease in seizures Seizure-free days 9 16 >50%
Slide 12: 11-Year Old Female
11-Year Old Female Pre-ganaxolone treatment Post-ganaxolone treatment % Change Seizures multiple absences and spasms per day; severe behavior disturbance; frequent respiratory infections reduction of seizure frequency and intensity; improved quality of life; relieved by burden of epilepsy Seizure fr
Slide 13: Why Ganaxolone in CDKL5 Disorder?
Why Ganaxolone in CDKL5 Disorder? 13 Remarkable response in efficacy, safety and behavior with ganaxolone in this extremely rare, refractory patient population that has little success in controlling their seizures with existing treatment regimens Magnitude of Effect The children with improved seizur
Slide 14: Thank you
Thank you Follow @MarinusPharma on Twitter!
Slide 15: Marinus Pharmaceuticals
M‘SARINUS Follow @MarinusPharma on Twitter! PHARMACEUTICALS
Marinus Pharmaceuticals — Corporate Update (September 2017) on 6ix